Lupin is currently trading at Rs. 827.10, up by 7.70 points or 0.94% from its previous closing of Rs. 819.40 on the BSE.
The scrip opened at Rs. 815.00 and has touched a high and low of Rs. 828.80 and Rs. 811.60 respectively. So far 79268 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 807.00 on 06-Dec-2017.
Last one week high and low of the scrip stood at Rs. 828.80 and Rs. 807.00 respectively. The current market cap of the company is Rs. 37094.65 crore.
The promoters holding in the company stood at 46.80%, while institutions and non-institutions held 40.05% and 13.14% respectively.
Lupin is recalling 1.11 lakh units of Duloxetine delayed-release capsules from the US market. The company is recalling 1,11,648 units of Duloxetine delayed-release capsules USP, in the strength of 30 mg, on account of failed dissolution specification. The drug was manufactured by Lupin in Goa plant. The ongoing voluntary nationwide recall is a class III recall.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
